News

Single-dose drug to quash anxiety passes another trial milestone

December 20, 2023/

An effective single-dose, long-term treatment for anxiety could be within reach, with the phase 2b clinical trial of MM-120 reported to have passed the stage with flying colors. The makers, MindMed, now plan to hold an end-of-phase meeting with the US Food and Drug Administration (FDA) in early 2024, and then get a phase 3 trial under way.

 

By Bronwyn Thompson


Click here to read the story.

Related Stories

  1. $11M University of Montana Research Center Targets Improving Health for All Montanans
  2. Efforts to build ‘Innovation Campus’ in Missoula still alive

Leave a Comment

You must be logged in to post a comment.

MATR Sponsor (view all)


The Missoula Chamber of Commerce advances the quality of life in Missoula by advocating for a healthy, responsible & diverse business environment & by providing resources that help businesses succeed. Contact Sharon Morren, Director of Membership, [email protected] to join.

MATR Supporters (view all)


Make Your Future in the College of Business

Working closely with GFDA’s economic development team, HPF helps Montana businesses access the capital they need to expand, modernize, and strengthen local communities.

The Great Falls Development Alliance delivers aggressive, award-winning economic development support for business attraction, expansion, and retention.